Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer

被引：10

作者：

Liu, Yi-Fu ^{[1
]}

Fu, Sheng-Qiang ^{[1
]}

Yan, Yu-Chang ^{[1
]}

Gong, Bin-Bin ^{[1
]}

Xie, Wen-Jie ^{[1
]}

Yang, Xiao-Rong ^{[1
]}

Sun, Ting ^{[1
]}

Ma, Ming ^{[1
]}

机构：

[1] Nanchang Univ, Affiliated Hosp 1, Dept Urol, Nanchang 330000, Jiangxi, Peoples R China

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2021年 / 15卷

关键词：

gonadotropin-releasing hormone; prostate cancer; degarelix; relugolix; ANDROGEN-DEPRIVATION THERAPY; ANTIANDROGEN FLARE PROTECTION; URINARY-TRACT SYMPTOMS; III EXTENSION TRIAL; OF-LIFE IMPROVEMENT; OPEN-LABEL; GNRH ANTAGONIST; PHASE-II; JAPANESE PATIENTS; 1-ARM CROSSOVER;

D O I：

10.2147/DDDT.S291369

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Gonadotropin-releasing hormone (GnRH) receptor agonists are still the most commonly used androgen deprivation treatment (ADT) drugs for prostate cancer in clinical practice. Currently, the GnRH receptor antagonists used for endocrine therapy for prostate cancer primarily include degarelix and relugolix (TAK-385). The former is administered by subcutaneous injection, while the latter is an oral drug. Compared to GnRH agonists, GnRH antagonists reduce serum testosterone levels more rapidly without an initial testosterone surge or subsequent microsurges. This review focuses on the mechanism of action of GnRH antagonists and agonists, the developmental history of GnRH antagonists, and emerging data from clinical studies of the two antagonists used as endocrine therapy for prostate cancer.

引用

页码：639 / 649

页数：11

共 50 条

[21] Eliminating Hormones With Orally Active Gonadotropin-releasing Hormone Antagonists [J].

Kotlyar, Alexander M. ;

Pal, Lubna ;

Taylor, Hugh S. .

CLINICAL OBSTETRICS AND GYNECOLOGY, 2021, 64 (04) :837-849

[22] Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis [J].

Kunath, Frank ;

Borgmann, Hendrik ;

Bluemle, Anette ;

Keck, Bastian ;

Wullich, Bernd ;

Schmucker, Christine ;

Sikic, Danijel ;

Roelle, Catharina ;

Schmidt, Stefanie ;

Wahba, Amr ;

Meerpohl, Joerg J. .

BMJ OPEN, 2015, 5 (11)

[23] Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer [J].

Clinton, Timothy N. ;

Woldu, Solomon L. ;

Raj, Ganesh V. .

EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (08) :825-832

[24] Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety [J].

Raja, T. ;

Sud, Rahul ;

Addla, Sanjai ;

Sarkar, Kalyan K. ;

Sridhar, P. S. ;

Talreja, Vikas ;

Jain, Minish ;

Patil, Ketaki .

INDIAN JOURNAL OF CANCER, 2022, 59 :S142-S159

[25] Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer [J].

Gandaglia, Giorgio ;

Sun, Maxine ;

Huc, Jim C. ;

Novara, Giacomo ;

Choueiri, Toni K. ;

Nguyen, Paul L. ;

Schiffmann, Jonas ;

Graefen, Markus ;

Shariat, Shahrokh F. ;

Abdollah, Firas ;

Briganti, Alberto ;

Montorsi, Francesco ;

Quoc-Dien Trinh ;

Karakiewicz, Pierre I. .

EUROPEAN UROLOGY, 2014, 66 (06) :1125-1132

[26] Gonadotropin-releasing hormone receptors in prostate tissue [J].

Bono, AV ;

Salvadore, M ;

Celato, N .

ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY, 2002, 24 (04) :221-227

[27] Gonadoliberin (Gonadotropin-Releasing Hormone), Its Agonists and Antagonists [J].

Holicka, Martina ;

Vyslouzil, Jakub ;

Kubova, Katerina ;

Muselik, Jan ;

Vetchy, David .

CHEMICKE LISTY, 2021, 115 (10) :516-523

[28] A potential new use for gonadotropin-releasing hormone antagonists [J].

Aust, TR ;

Sklavounos, J ;

Kingsland, CR ;

Gazvani, R .

FERTILITY AND STERILITY, 2003, 80 (03) :641-642

[29] Effect of lipidated gonadotropin-releasing hormone peptides on receptor mediated binding and uptake into prostate cancer cells in vitro [J].

Stephenson, Rachel ;

Varamini, Pegah ;

Butcher, Neville ;

Minchin, Rodney ;

Toth, Istvan .

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2014, 10 (08) :1799-1808

[30] Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist [J].

Crawford, E. David ;

Hafron, Jason M. ;

Debruyne, Frans ;

Wallis, Christopher ;

Chang, Steven ;

Garnick, Marc B. .

JOURNAL OF UROLOGY, 2024, 211 (01) :63-70

← 1 2 3 4 5 →